Results: OPTI

views

OptiBiotix Health (OPTI) was one of our tips of the year, with we anticipating financial progress as its deals for its compounds expand and further deals kick-in. It has now announced that a further human volunteer study on its cholesterol-reducing probiotic LP_LDL - on a different population group of hypercholesterolemic adults - has shown “at six weeks, when volunteers taking placebo were compared to those taking LP_LDL, there were statistically significant changes to clinically important cardiovascular risk”, including “34.2% reduction in total cholesterol (p=0.001)”.

NEWSFLOW

views

OptiBiotix Health (OPTI) has followed a sales agreement with Apollo Hospitals Enterprises for its GoFigure weight management product range in India with an agreement for GoFigure and SlimBiome Medical in Saudi Arabia (KSA). Is this further encouraging progress or just more flannel?

views

OptiBiotix Health (OPTI) has announced the launch of a new sports nutrition product range, LeanBiome, with a supply & licensing agreement with “a leading global player in beauty & nutrition”. What of a current share price response up to 42.5p?

NEWSFLOW

views

As predicted HERE the print going through late on Friday was Optibiotix (OPTI) dumping £2 million worth of Skinbiotherapeutics (SBTX) at 55p. I told you that this would happpen weeks ago producing more bluster and fake denials from all involved. Fuckers! The release this morning insults the intelligence of we loyal shareholders in both companies yet again. Stuart, Steve, posh PR bird Melanie Toyne-Sewell and the scumbags at Cenkos do you think we are idiots? You treat us as if we are.

views

Life sciences compounds developer OptiBiotix Health (OPTI) has announced results for the first of calendar 2021, emphasising “sales of LP_LDL and SlimBiome of £1.076m, a 44.5% increase over H1:2020… pleasing given the continued uncertain global economic environment and challenges of the subsequent waves of COVID-19, particularly in countries like India and the USA”. The shares have currently responded slightly higher, to 50p.

NEWSFLOW

views

This event was held on 9 September and what follows is a transcript of the more interesting Q&As. There is oodles of jam tomorrow but I sense that the time for that working has passed. Steve O’Hara and Optibiotix (OPTI) need to start delivering jam today to drive a re-rate of any sort, let alone from £50 million to £1 billion as suggested in Q1.

views

Cenkos is house broker to Optibiotix (OPTI) so it is biased. I own a truck load of shares in Optibiotix so I am biased. But this 34 page note is detailed and may give you pause for thought. Steve O'Hara is doing an online presentation and Q&A tonight. I am not attending as I am washing my hair. Brokers notes and investor love-ins are all very well what I want to see now are material revenues and profits. And, while notes and presentations may tickle the share price, a material re-rate can only come from those sales and profits being delivered. I still believe that it will happen but I understand that others are bored of waiting. The full note is below.